MYDA Advisors’s Krystal Biotech KRYS Stock Holding History

MYDA Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,000	Closed	-$296K	–	115
2019 Q1	$296K	Buy	+9,000	New	+$212K	0.15%	91

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MYDA Advisors's KRYS Position: Q2 2019 in Review

MYDA Advisors sold out of Krystal Biotech (KRYS) in Q2 2019, closing a stake of 9,000 shares — an estimated $296K sold.

MYDA Advisors first reported a position in KRYS in Q1 2019 and held it in 1 quarter. The position peaked at $296K in Q1 2019. 76 funds tracked by Wall St. Rank hold KRYS as of Q2 2019.

MYDA Advisors reported no remaining Krystal Biotech position as of Q2 2019 after selling out during the quarter.
MYDA Advisors sold 9,000 Krystal Biotech shares in Q2 2019, an estimated $296K.
MYDA Advisors first reported a position in Krystal Biotech in Q1 2019 and held it in 1 quarter.
MYDA Advisors's Krystal Biotech position peaked at $296K in Q1 2019.
76 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2019.

Based on MYDA Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.